Raymond James Financial
GPCR icon

Raymond James Financial’s Structure Therapeutics GPCR Stock Holding History

Raymond James Financial’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.18M Buy
45,139
+751
+2% +$51.4K ﹤0.01% 3298
2025
Q4 		$3.09M Buy
+44,388
New +$1.81M ﹤0.01% 2911
2025
Q3 		– Sell
-6,229
Closed -$129K – 5687
2025
Q2 		$129K Buy
+6,229
New +$137K ﹤0.01% 4734

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Raymond James Financial's GPCR Position: Q1 2026 in Review

Raymond James Financial increased its Structure Therapeutics (GPCR) stake by 1.7% in Q1 2026, buying an estimated $51.4K and bringing the position to 45,139 shares worth $2.18M. The position accounts for ﹤0.01% of the portfolio, ranked #3298.

Raymond James Financial first reported a position in GPCR in Q2 2025 and has held it in 3 quarters since. The position peaked at $3.09M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Raymond James Financial held 45,139 shares of Structure Therapeutics worth $2.18M as of Q1 2026.
  • Raymond James Financial bought 751 Structure Therapeutics shares in Q1 2026, an estimated $51.4K.
  • Structure Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3298 holding.
  • Raymond James Financial first reported a position in Structure Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Raymond James Financial's Structure Therapeutics position peaked at $3.09M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.